Imaging substance P receptors (NK1) in the living human
brain using positron emission tomography
by
Hargreaves R.
Merck Research Laboratories,
West Point, PA 19486, USA.
Richard_Hargreaves@merck.com
J Clin Psychiatry 2002;63 Suppl 11:18-24

ABSTRACT

Substance P (SP)-neurokinin-1 (NK1) receptor pathways have been implicated in the pathophysiology of emesis and depression. Autoradiographic studies in monkey and human brains have shown a high expression of NK1 receptors in regions important for the regulation of affective behaviors and the neurochemical response to stress. Furthermore, clinical studies demonstrated that treatment with the SP (NK1 receptor) antagonist (SPA) aprepitant (also known as MK-0869) significantly improves depression symptoms and reduces the incidence of chemotherapy-induced nausea and vomiting. An important objective of all neuroscience drug discovery and development programs is to establish the correlation between dose, receptor occupancy, and the observed clinical effect (the dose-response relationship). These goals can be achieved using radioactive receptor-specific tracers and dynamic noninvasive brain imaging modalities, such as positron emission tomography (PET). In the SPA program, a tracer [18F]SPA-RQ was chosen for PET studies on the basis of several criteria, including high affinity for the NK1 receptor, low nonspecific binding, and good blood-brain barrier penetration. PET imaging studies in rhesus monkeys and humans confirmed these tracer features and established the usefulness of this probe for in vivo NK1 receptor occupancy studies. Subsequent PET occupancy studies in humans predicted that very high levels of central NK1 receptor occupancy (> 90%) were associated with therapeutically significant antidepressant and antiemetic effects. Future PET imaging studies will focus on quantification of NK1 receptor expression in depressed patients, both before and after successful treatment with antidepressants.

SPAs
Aprepitant
21st Century
Pregnenolone
Buprenorphine
Neuropeptide-Y
NMDA antagonists
Substance P: review
New antidepressants
Enkephalinase inhibitors
Substance P antagonists
Neurokinins/substance P
New substance P antagonists
Nitric oxide synthase inhibitors
Substance P and major depression
Aprepitant: lack of antidepressant efficacy?
Effects on sleep, mood, and neuroendocrine function

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family